Leap Therapeutics Inc (LPTX)
3.385
-0.10
(-2.73%)
USD |
NASDAQ |
Jan 08, 16:00
3.30
-0.08
(-2.51%)
Pre-Market: 08:53
Leap Therapeutics SG&A Expense (Quarterly): 2.94M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
Inovio Pharmaceuticals Inc | 8.614M |
CervoMed Inc | 2.211M |
AIM ImmunoTech Inc | 3.079M |
Protalix BioTherapeutics Inc | 2.595M |
Armata Pharmaceuticals Inc | 3.244M |